Introduction
Over the past two decades, significant advances have been made to improve the morbidity and mortality in sickle cell disease (SCD). [1] [2] [3] [4] Although hydroxyurea therapy and chronic red blood cell transfusion may decrease the complications of chronic organ damage, 5, 6 both treatment modalities require long-term compliance to prevent irreversible end-organ damage. Currently, however, hematopoietic stem cell transplantation (HCT) provides the only cure for SCD.
Multicenter trials have shown that HCT in SCD is associated with an excellent outcome with overall and event-free survivals of 90% and approximately 85%, respectively. [7] [8] [9] Important indications include stroke, history of recurrent hospitalizations or exchange transfusion for acute chest syndrome, and recurrent vaso-occlusive pain crisis (X 3 episodes per year).
Currently, age o16-years old is a recommended inclusion criteria for transplantation in SCD. 10 An early age at transplant before the onset of severe chronic organ damage is likely to provide the best outcomes. Thus, it is important to identify SCD patients early as serious candidates for HCT.
We report our single center's experience in children with SCD who underwent HCT using myeloablative conditioning including one patient who received a second transplant using a reduced intensity conditioning regimen (RIC) for progressively decreasing donor chimerism.
Methods

Patients
Between November 1997 and June 2005, a total of 10 patients with SCD (Hb SS/HbSb 0 thalassemia) received HCT using a myeloablative conditioning regimen from HLA-matched sibling donors at the University of Mississippi Medical Center. One of these patients received a second transplant using an RIC regimen for low mixed donor chimerism. Patient characteristics are presented in Table 1 . This retrospective study was approved by the Institutional Review Board of the University of Mississippi Medical Center. Informed written consent/assent was obtained from patients and/or their parents or guardians before transplantation.
Treatment regimen
Myeloablative conditioning regimen before transplantation consisted of a combination of busulfan (days À9 to À6 at 0.8 mg/kg IVq6), horse antithymocyte globulin (days À4 to À2 at 30 mg/kg) and cyclophosphamide (days À5 to À1 at 50 mg/kg) with MESNA for bladder protection. Twelve months after HCT, patient No 10 received a donor lymphocyte infusion (total nuclear cell count 1.05 Â 10 8 , CD3 cells/kg 4.4 Â 10 6 , CD34 cells/kg 2.9 Â 10 6 ). Subsequently, 26 months after the first HCT, the same patient received a second HCT using an RIC consisting of alemtuzumab (Campath; days À8 to À4 at 10 mg per day), fludarabine (days À7 to À3 at 30 mg/m 2 ) and melphalan (day À2 at 140 mg/m 2 ). The majority of patients given myeloablative conditioning received methotrexate and cyclosporine (CSP) for prevention of acute GVHD (Table 2) . CSP levels were monitored closely to maintain levels between 150 and 300 ng/ml. Most patients had CSP discontinued within 6 months after transplantation. CSP was stopped in three patients who developed seizures; two out of the three patients had the CSP changed to mycophenolate mofetil (MMF). The patient with the RIC regimen received tacrolimus and MMF for GVHD prophylaxis; tacrolimus levels were followed closely to maintain levels between 5 and 15 ng/ml. Therapeutic monitoring was performed when a steady state was established. At each follow-up clinic visit, patients were monitored for GVHD severity according to published international grading criteria.
11,12
Supportive care Institutional standard requires that all blood products are leukocyte-poor; all patients who were seronegative for cytomegalovirus received cytomegalovirus antibody screened blood. Screening cytomegalovirus PCR was intermittently performed until day 100 after transplant. All patients were commenced on phenytoin as anticonvulsant prophylaxis at initiation of CSP and until CSP therapy was discontinued. Phenytoin levels were followed at every clinic visit with the necessary dose adjustment. Platelet count was monitored for platelet engraftment (platelet count 450 000/ml) and platelet transfusions were given as needed. Subcutaneous G-CSF (Neupogen) was instituted at the time of HCT and continued until neutrophil engraftment (ANC 4500/ml for 3 consecutive days).
Assessment of disease status and follow-up after transplantation All patients were monitored regularly with height and weight for assessment of growth, complete blood count, reticulocyte count and quantification of hemoglobin types by high performance liquid chromatography. In addition, history and physical examinations were performed at each clinic visit for GVHD, recurrence of manifestations of SCD, Lansky/Karnofsky score or for any other problems related to HCT. In most patients, long-term follow-up studies included MRI/MR angiogram to monitor for any worsening or resolution of earlier abnormal findings, thyroid functions tests (thyroid stimulating hormone and free T4), endocrine function (measurement of testosterone or estradiol, luteneizing hormone, follicle-stimulating hormone to monitor for any evidence of premature ovarian failure especially in the adolescent females) and pulmonary function tests (based on common methods for comparison of reference values). 13 Actual lung volumes were compared with predicted values from age-and sex-matched controls to generate a percentage of the predicted value for each subject. Mild restrictive pulmonary disease was defined as 80% of predicted normal, or 1 standard deviation (s.d.) below normal, moderate was defined as 60% of predicted 
Chimerism studies
After extraction of DNA from whole blood, hematopoietic donor cell chimerism was analyzed in nine patients by polymerase chain reaction amplification of eight short tandem repeat loci and capillary electrophoresis using Applied Biosystems Model 3100 (Foster City, CA, USA), with analysis of relative peak heights of each locus. On most patients, donor chimerism was studied at 1, 2, 4, 6 and 12 months after transplantation and yearly thereafter.
Statistical analysis
A Kaplan and Meier overall and event-free survival was estimated by using SigmaPlot statistical software. Event was defined as death, graft rejection (o5% donor chimerism), or recurrence of SCD (the presence of symptoms of SCD with an elevated HbS% fraction). Thus, one patient with a donor chimerism level of 15% and a corresponding HbS% fraction of 59% with possible symptoms of SCD was considered to have rejection.
Results
Patient characteristics
Ten patients (six males, four females) with SCD received HCT at the University of Mississippi Medical Center between 1997 and 2005. Eight patients had hemoglobin SS disease and two patients had HbSb 0 thalassemia. The median age of HCT was 10.1 (range 2.8-16.3) years. The indications were cerebrovascular accident (n ¼ 6), abnormal transcranial Doppler (n ¼ 2), acute chest syndrome (n ¼ 1) and recurrent vaso-occlusive disease (n ¼ 1). All donors were HLA-identical siblings; six patients received bone marrow, two patients received G-CSF mobilized peripheral blood stem cells, one patient received umbilical cord blood and one patient received both umbilical cord blood and bone marrow from the same donor. The median number of packed red blood cell units transfused before transplant was 9 (range 1-99). Three patients had gallstones and four patients had high ferritin levels (median 3550 and range 1110-4380 ng/ml) before transplant.
Other comorbid conditions before transplant included asthma (n ¼ 2), hemosiderosis (n ¼ 4; two of which were confirmed by liver biopsy). One patient had a positive antibody screen before transplant (anti-A 128, anti-B 64 blood group titer levels). None of the patients had received hydroxyurea or splenectomy before transplantation.
Hematologic recovery
The median number of days to neutrophil engraftment and platelet engraftment (450 000/ml) was 14.5 days (range 11-44 days) and 19.5 days (range 13-101 days), respectively. Patient No 10 had neutrophil and platelet engraftment at 14 and 18 days, respectively, using the myeloablative conditioning regimen, and 15 and 29 days, respectively, using the RIC regimen.
Complications after HCT Four patients had acute Xgrade II GVHD and four patients had limited chronic (skin) GVHD. One patient experienced extensive chronic GVHD (Table 2) . Currently, three females are 414 years, and two of the three females have premature ovarian failure. Follow-up in seven out of nine patients shows no evidence of thyroid dysfunction. One of the two patients with asthma had mild restrictive pulmonary disease. Three patients (patient No 2, 7 and 9) had a seizure at days 15, 44 and 345, respectively, with MRI changes suggestive of posterior leukoencephalopathy most likely secondary to CSP toxicity. However, none of these patients had any sequelae. Patient No 10 had ataxia related to phenytoin toxicity that resolved with discontinuation of phenytoin. Five out of six patients that had follow-up MRI/MRA showed no change from earlier studies. At day þ 28, patient No 6 had extensive intracranial hemorrhage and neurologic devastation with a Lansky of 10%, subsequently complicated by failure-to-thrive and diabetes insipidus. Patient died at day þ 270 from multiorgan failure secondary to sepsis. Patient No 8 with a positive titer antibody screen before transplant developed alloimmune hemolytic anemia and responded to a course of steroids.
Engraftment
Follow-up donor chimerism levels varied from 15 to 100% (Table 2 ). Patient No 10 had a gradual decline to a donor chimerism of 15% and the HbS fraction increased to 59% (Figure 1 ). During this period of mixed donor chimerism, the patient had two hospitalizations for pneumonia that could possibly have been because of acute chest syndrome. Twenty-six months after the first HCT, patient subsequently received a second HCT that led to full donor engraftment.
Outcome Currently, 9 out of 10 patients are alive with a median follow-up of 5.5 (range 2.9-9.9) years. The Kaplan-Meier 5 year overall and event-free survival probabilities with our 
Discussion
Despite our relatively small number of patients, the transplant-related morbidity and outcomes are mostly consistent with multicenter trials. [7] [8] [9] Seizure secondary to CSP with MRI changes suggestive of posterior leukoencephalopathy was commonly seen in our patients even with the use of anticonvulsant prophylaxis. A multicenter trial showed that 7 out of 16 patients with seizures had posterior leukoencephalopathy secondary to CSP toxicity suggesting that an alternative medication for GVHD prophylaxis should be considered. 9 Walters et al. 7 have shown in a multicenter trial that of 10 engrafted patients with prior stroke, all had stable or improved MRI scan. All our five patients that had follow-up MRI/MRA showed stable disease with no worsening or improvement. However, another study found that five of eight patients had new, persistent changes 7 months to 6.5 years after HCT. 14 Multicenter trials have shown that about 20% of patients suffer from Xgrade II GVHD using a myeloablative conditioning regimen. [7] [8] [9] In our center's experience, 40% (4 out of 10 patients) had acute grade II GVHD although none of the patients had acute grade III/IV GVHD. Furthermore, 5 out of 10 patients suffered from chronic GVHD, which is higher than the 12-20% reported in multicenter trials. [7] [8] [9] The higher incidences of GVHD is most likely because of our small sample size, and even though two patients had PBSC, it is difficult to conclude whether chronic GVHD was partly related to stem cell source, combination of immunosuppressive therapy or age at transplant.
Three patients (30%) developed stable mixed donor chimerism at a median of 4.1 years. Multicenter trials report stable mixed chimerism in about 10-30% of patients. 7, 9 This variability could be related to factors such as cell dose as well as the conditioning regimen.
Bernaudin et al. 9 have shown that the addition of antithymocyte globulin significantly influences the degree of donor chimerism. Although the majority of patients with SCD achieve complete donor chimerism after a myeloablative HCT, the cumulative incidence of graft rejection or recurrence of SCD remains at about 10%. [7] [8] [9] 15 Follow-up chimerism studies in patient No 10 showed some evidence of durable mixed donor chimerism; however, with the elevated HbS% fraction and the history of two hospitalizations for pneumonia (or possible acute chest syndrome), it was decided to proceed with a second transplant using a RIC regimen to minimize toxicity. This second transplant may have provided the extra bone marrow space required to 'boost' the low mixed donor chimerism and sustain normal erythropoiesis. Second, HCT has been more widely performed in other hematological conditions such as thalassemia. Gaziev et al. 16 have shown that in a total of 16 thalassemia patients given a second transplant using a RIC regimen, the sustained engraftment rate was high (94%) with only one patient having primary graft failure. Nevertheless, the vasculopathy with the red blood cell sickling phenomenon, endotheilial activation and platelet activation unique to SCD does not occur in thalassemia and therefore, the reported characteristics of a second HCT in thalassemia may not be directly applicable to patients with SCD.
In our center's experience, three out of four females 414-years old developed premature ovarian failure with amenorrhea as the chief complaint. However, one study showed that 19 out of 21 (95%) women transplanted for other conditions such as leukemia developed ovarian failure after a myeloablative conditioning regimen. 17 Thus, all families and female patients with SCD should be offered ovarian cryopreservation and counseled about the high risk of ovarian failure after HCT, and treated with hormone replacement therapy to prevent any serious psychological and medical effects.
Multicenter trials have shown that HCT in SCD is associated with an excellent outcome. Our single center's experience with a relatively small number of patients shows an overall and event-free survivals of 90 and 77%, respectively, with tolerable toxicities. HCT for SCD should be performed at an early age for a broad range of indications. Hematopoietic cell transplantation in sickle cell disease S Majumdar et al
